Eyenovia (EYEN) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1-year price targets for Eyenovia's shares. Their EYEN share price forecasts range from $12.00 to $12.00. On average, they predict the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 317.4% from the stock's current price.
View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts.

Eyenovia's stock was trading at $1.63 on January 1st, 2023. Since then, EYEN shares have increased by 76.4% and is now trading at $2.8750.
View the best growth stocks for 2023 here.

Eyenovia saw a increase in short interest in May. As of May 15th, there was short interest totaling 723,500 shares, an increase of 118.2% from the April 30th total of 331,600 shares. Based on an average daily trading volume, of 420,300 shares, the days-to-cover ratio is presently 1.7 days.
View Eyenovia's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our EYEN earnings forecast.

Eyenovia, Inc. (NASDAQ:EYEN) released its earnings results on Wednesday, November, 10th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. During the same period in the previous year, the business earned ($0.23) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX), Trevena (TRVN), Albireo Pharma (ALBO), BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS).

(EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

Eyenovia's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.69%), State Street Corp (0.22%), BKA Wealth Consulting Inc. (0.21%), BKA Wealth Consulting Inc. (0.21%), Jane Street Group LLC (0.11%) and Dimensional Fund Advisors LP (0.07%). Insiders that own company stock include Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev.
View institutional ownership trends.

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYEN stock can currently be purchased for approximately $2.88.

Eyenovia (NASDAQ:EYEN) has a market capitalization of $109.26 million and generates $14 million in revenue each year. The company earns $-28,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The official website for the company is www.eyenoviabio.com. The company can be reached via phone at (917) 289-1117 or via email at tbui@theruthgroup.com.